Back to Browse Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 4

The impact of SHS exposure on health status and exacerbations among patients with COPD

Authors Mark D Eisner, Carlos Iribarren, Edward H Yelin, Stephen Sidney, et al.

Published 6 May 2009 Volume 2009:4 Pages 169—176

DOI http://dx.doi.org/10.2147/COPD.S4681

Review by Single-blind

Peer reviewer comments 2

Mark D Eisner1,3, Carlos Iribarren3, Edward H Yelin2, Stephen Sidney3, Patricia P Katz2, Gabriela Sanchez3, Paul D Blanc1

1Division of Occupational and Environmental Medicine and Division of Pulmonary and Critical Care Medicine; 2Institute for Health Policy Studies, Department of Medicine, University of California, San Francisco, CA, USA; 3Division of Research, Kaiser Permanente, Oakland, CA, USA

Abstract: Secondhand smoke (SHS) is a major contributor to indoor air pollution. Because it contains respiratory irritants, it may adversely influence the clinical course of persons with chronic obstructive pulmonary disease (COPD). We used data from nonsmoking members of the FLOW cohort of COPD (n = 809) to elucidate the impact of SHS exposure on health status and exacerbations (requiring emergency department visits or hospitalization). SHS exposure was measured by a validated survey instrument (hours of exposure during the past week). Physical health status was measured by the SF-12 Physical Component Summary Score and disease-specific health-related quality of life (HRQL) by the Airways Questionnaire 20-R. Health care utilization for COPD was determined from Kaiser Permanente Northern California computerized databases. Compared to no SHS exposure, higher level SHS exposure was associated with poorer physical health status (mean score decrement −1.78 points; 95% confidence interval [CI] −3.48 to −0.074 points) after controlling for potential confounders. Higher level SHS exposure was also related to poorer disease-specific HRQL (mean score increment 0.63; 95% CI 0.016 to 1.25) and less distance walked during the Six-Minute Walk test (mean decrement −50 feet; 95% CI −102 to 1.9). Both lower level and higher level SHS exposure was related to increased risk of emergency department (ED) visits (hazard ratio [HR] 1.40; 95% CI 0.96 to 2.05 and HR 1.41; 95% CI 0.94 to 2.13). Lower level and higher level SHS exposure were associated with a greater risk of hospital-based care for COPD, which was a composite endpoint of either ED visits or hospitalizations for COPD (HR 1.52; 95% CI 1.06 to 2.18 and HR 1.40; 95% CI 0.94 to 2.10, respectively). In conclusion, SHS was associated with poorer health status and a greater risk of COPD exacerbation. COPD patients may comprise a vulnerable population for the health effects of SHS.

Keywords: chronic obstructive pulmonary disease, chronic bronchitis, pulmonary emphysema, tobacco smoke pollution

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Other article by this author:

COPD and cognitive impairment: the role of hypoxemia and oxygen therapy

Neeta Thakur, Paul D Blanc, Laura J Julian, et al

International Journal of Chronic Obstructive Pulmonary Disease 2010, 5:263-269

Published Date: 10 August 2010

Readers of this article also read:

Enhancement of osseointegration of polyethylene terephthalate artificial ligament by coating of silk fibroin and depositing of hydroxyapatite

Jiang J, Wan F, Yang JJ, Hao W, Wang YX, Yao JR, Shao ZZ, Zhang P, Chen J, Zhou L, Chen SY

International Journal of Nanomedicine 2014, 9:4569-4580

Published Date: 29 September 2014

Preparation of hippurate-zinc layered hydroxide nanohybrid and its synergistic effect with tamoxifen on HepG2 cell lines

Hussein Al Ali SH, Al-Qubaisi M, Hussein MZ, Zainal Z, Hakim MN

International Journal of Nanomedicine 2011, 6:3099-3111

Published Date: 1 December 2011

Safety of indacaterol in the treatment of patients with COPD

Donohue JF, Singh D, Kornmann O, Lawrence D, Lassen C, Kramer B

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:477-492

Published Date: 22 September 2011

Clinical utility of varenicline for smokers with medical and psychiatric comorbidity

Jon O Ebbert, Kirk D Wyatt, Ali Zirakzadeh, et al

International Journal of Chronic Obstructive Pulmonary Disease 2009, 4:421-430

Published Date: 17 November 2009

Management of invasive aspergillosis in patients with COPD: rational use of voriconazole

Florence Ader, Anne-Lise Bienvenu, Blandine Rammaert, et al.

International Journal of Chronic Obstructive Pulmonary Disease 2009, 4:279-287

Published Date: 24 July 2009

Asthma patients prefer Respimat® Soft Mist™ Inhaler to Turbuhaler®

Rick Hodder, Pat Ray Reese, Terra Slaton

International Journal of Chronic Obstructive Pulmonary Disease 2009, 4:225-232

Published Date: 26 May 2009

Fludarabine in the treatment of chronic lymphocytic leukemia: a review

Francesca Ricci, Alessandra Tedeschi, Enrica Morra, Marco Montillo

Therapeutics and Clinical Risk Management 2009, 5:187-207

Published Date: 4 March 2009

Prulifloxacin: a brief review of its potential in the treatment of acute exacerbation of chronic bronchitis

Francesco Blasi, Stefano Aliberti, Paolo Tarsia, PierAchille Santus, Stefano Centanni, Luigi Allegra

International Journal of Chronic Obstructive Pulmonary Disease 2007, 2:27-31

Published Date: 15 April 2007